| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 211.0 | 133.5 |
| Gross profit | 179.9 | 104.7 |
| Profit before tax | 2.3 | -16.0 |
| Net income | 2.0 | -16.2 |
| EPS (diluted, $ a share) | $0.03 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +58.0% |
|---|---|
| Gross margin | 85.2% |
| Operating margin | 0.4% |
10-Q filed with the SEC, NYSE: GKOS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Glaukos Corp: key numbers
- Share price
- $244.88Close, Nov 16
- Market cap
- $14.5B
- Shares outstanding
- 59.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Glaukos Corp
All →Glaukos President & COO Joseph E. Gilliam Sells $11.1M of Stock
Joseph E. Gilliam, President & COO, sold 44,917 shares of Glaukos Corp at $243.41 to $248.42 a share (average $246.32) in 6 transactions, worth $11.1M in total on Nov 12, 2026. Shares held after the trade: 71,602 (-0.4%).
- Value
- $11.1M
- Shares
- 44,917
- Average price
- $246.32
- Role
- President & COO
- Holding change
- -0.4%
- Trade date
- Nov 12, 2026
Glaukos Investor Presentation
Glaukos Corporation filed a formal investor presentation dated November 2026 to be used in meetings with investors and stakeholders. The presentation covers the company's strategic outlook, including the commercialization of its iDose TR and Epioxa therapies.
Glaukos Director Gilbert H. Kliman Sells $632K of Stock
Gilbert H. Kliman, Director, sold 2,500 shares of Glaukos Corp at $253.00 a share, worth $632K in total on Nov 4, 2026. Shares held after the trade: 37,406 (-6.3%).
- Value
- $632K
- Shares
- 2,500
- Price
- $253.00
- Role
- Director
- Holding change
- -6.3%
- Trade date
- Nov 4, 2026
Glaukos Chief Development Officer Tomas Navratil Sells $10.6M of Stock
Tomas Navratil, Chief Development Officer, sold 44,436 shares of Glaukos Corp at $237.54 to $240.52 a share (average $238.97) in 4 transactions, worth $10.6M in total on Oct 30, 2026. Shares held after the trade: 37,328 (-14.7%).
- Value
- $10.6M
- Shares
- 44,436
- Average price
- $238.97
- Role
- Chief Development Officer
- Holding change
- -14.7%
- Trade date
- Oct 30, 2026
Glaukos Financial Results
Glaukos Corporation reported record third-quarter 2026 net sales of $211.0 million, a 58% increase year-over-year, driven by strong performance in its U.S. Glaucoma and Corneal Health segments. The company achieved GAAP net income of $2.0 million and significantly raised its full-year 2026 revenue guidance while introducing a preliminary 2027 revenue target of $1 billion.
- Term
- Q3 2026
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa.”
Thomas Burns, Glaukos chairman and chief executive officer
Glaukos Chief Development Officer Tomas Navratil Sells $251K of Stock
Tomas Navratil, Chief Development Officer, sold 1,527 shares of Glaukos Corp at $163.93 to $165.60 a share (average $164.45) in 3 transactions, worth $251K in total on Oct 5, 2026. Shares held after the trade: 69,291 (-0.4%).
- Value
- $251K
- Shares
- 1,527
- Average price
- $164.45
- Role
- Chief Development Officer
- Holding change
- -0.4%
- Trade date
- Oct 5, 2026